Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Zhi Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Huanghuai University Industry Innovation & Research and Development Institute, Huanghuai University, Zhumadian, Henan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hydroxamic Acids, Histone Deacetylase Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: Huanghuai University.
Abstract (Originalsprache)
Cancer, as a fatal metastatic disease, exerts a deep‐seated and extensive influence on human health, impacting not just the physical condition of patients but also their psychological state and social lives. Hydroxamic acid derivatives, as exceptional histone deacetylase (HDAC) inhibitors, could regulate diverse cellular pathways, cause cell cycle arrest, and promote programmed cell death. Consequently, hydroxamic acid derivatives demonstrate significant efficacy in combating a wide range of cancers, including hematological malignancies and solid tumors. Moreover, diverse hydroxamic acid derivatives have already been applied in clinics or are currently undergoing clinical trials for cancer therapy, revealing that hydroxamic acid derivatives hold great promise as scaffolds for exploring novel anticancer agents. This review aims to comprehensively summarize the current scenario of hydroxamic acid derivatives with in vivo antitumor therapeutic potential, along with their metabolic profiles, pharmacokinetic properties, toxicity, and mechanisms of action, developed since 2020, to facilitate further rational design of safer and more potent candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huanghuai University Industry Innovation & Research and Development Institute, Huanghuai University, Zhumadian, Henan, China.
- School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, China.
ORCID-Profile: Zhi Xu
Förderung
- Huanghuai University
Zitieren
APA
Xu, Z., & Liu, J. (2025). Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70178
Vancouver
Xu Z, Liu J. Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70178
BibTeX
@article{Xu2025,
author = {Xu, Zhi and Liu, Junna},
title = {Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70178}
}
EUVIMED